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Aims: To examine trends in heart failure hospitalization rates and risk of readmissions following 
an incident HF hospitalization. 
Methods and Results: During 2000-2014, w
Norway Project  109 hospitalizations with HF as primary diagnosis. Trends of incident and 
total (incident and recurrent) HF hospitalization rates were analyzed using negative binomial 
regression models. Changes over time in 30-day and three-year risk of HF recurrences or CVD-
related readmissions were analyzed using Fine and Grey competing risk regression, with death as 
competing events. 
Age-standardized rates declined on average 1.9% per year in men and 1.8% per year in women 
for incident HF hospitalizations (both P trend<0.001) but did not change significantly in either men 
or women for total HF hospitalizations.  
In men surviving the incident HF hospitalization, 30-day and three-year risk of a HF recurrent 
event increased 1.7% and 1.2% per year, respectively. Similarly, 30-day and three-year risk of a 
cardiovascular (CVD)-related hospitalization increased 1.5% and 1.0% per year, respectively (all 
P trend<0.001). No statistically significant changes in the risk of HF recurrences or CVD-related 
readmissions were observed among women. In-hospital mortality for a first and recurrent HF 
episode declined over time in both men and women.  
Conclusions: Incident HF hospitalizations rates declined in Norway during 2000-2014. An 
increase in the risk of recurrences in the context of reduced in-hospital mortality following an 
incident and recurrent HF hospitalization led to flat trends of total HF hospitalization rates.  
Keywords: Heart failure, hospitalization rates, readmission rates, Norway, epidemiology 
 
Introduction
Heart failure (HF) affects 38 million people worldwide and is the most common reason for 
in high-income countries.1 HF places a considerable burden 
to health care systems due to multiple hospitalizations and high treatment costs.  
Several factors influence HF occurrence in the general population. Decline in the incidence of 
heart disease reduces the risk of HF while improved survival following an acute event exposes 
survivors to more years at risk of developing HF.2 Aging of the population also increases the risk 
of HF through various mechanisms. Aging is associated with structural and functional changes of 
the heart muscle and/or valves,3 leading to increased risk of HF. Further, treatment of the 
underlying conditions are suboptimal4 or less successful in the elderly, increasing the risk of 
adverse outcomes, including HF.  
To add to the complexity, population trends in other risk factors for HF such as obesity, 
diabetes, hypertension, and smoking also influence HF rates.5 
Previous publications have shown declines in first-time (incident) HF hospitalization rates in 
many Western countries during recent years.6-9 Less consistent have been results of trend analyses 
for total (incidence and recurrent) HF hospitalization rates, showing declines in some countries10-13 
and increase in others.14 Although incident events account for the majority of HF-related 
hospitalizations, recurrences are regarded as an indicator of hospital performance.15 Nevertheless, 
information on the relationship between trends in incident and total HF hospitalization and the role 
of recurrences in this relationship is sparse.  
Therefore, the current study aimed at exploring trends in incident and total HF hospitalization 
rates over a 15-year period using national data from Norway. In addition, we analyzed changes in 
short (30 days) and long (three years) term risk of HF recurrences and CVD-related readmission 
following discharge from the incident HF hospitalization. 
Methods 
Data Sources 
The Cardiovascular Disease in Norway Project (CVDNOR) contains information on all hospital 
stays with a CVD-related diagnosis [International Classification of Diseases (ICD) 9 codes 390-
459 or ICD-10 codes, I00-I99] in Norway during 1994-2014. The information was retrieved 
directly from the Patient Administrative System (PAS) of all somatic hospitals during 1994-2009 
and from the Norwegian Patient Registry after 2009. Detailed information on data collection, 
content and quality have been previously published.16-18 A personal, unique project-specific 
number assigned to each individual allowed us to follow study participants at the individual level 
for subsequent hospitalizations and/or death. Information on deaths was retrieved from the Cause 
of Death Registry.   
Study design, population and definitions 
This is a nationwide, retrospective cohort study linking hospitalization data to several national 
registers and data sources in Norway. 
For the main analyses, we identified all individuals 15+ years, hospitalized with HF as primary 
discharge diagnosis (ICD-9 codes, 402.01, 402.11, 402.3, 402.7, 402.91, 425.4, 425.5, 425.9, 428, 
428.x; ICD-10 codes, I09.81, I11.0, I50 and I50.) in Norway, 1994-2014.  
Using a fixed lookback (LP) period of six years, we identified individuals without prior 
hospitalizations with HF as either primary or secondary diagnosis (incident cases). Therefore, the 
study period was confined to 2000-  hospitalization 
with HF as primary diagnosis following discharge from the incident HF hospitalization.  
Statistical Analyses
Continuous variables are presented as means and standard deviations (SD) and categorical 
variables as proportions. Differences in baseline characteristics were tested using clustered linear 
(for continuous variables) and logistic (for categorical variables) regression models, adjusted for 
age, with patient ID as the cluster variable. This was done to account for the dependency caused 
by multiple hospitalizations for the same individual.  
We calculated age-standardized HF hospitalization rates for men and women separately, using 
the direct standardization method and the age distribution of Norwegian population in year 2000 as 
included individuals without previous HF hospitalizations (HF-free population). The population 
total HF hospitalizations included the total population of Norway. 
We plotted the age-standardized rates [overall and by admission type (acute versus non-acute) for 
years with available data (2010-2014)] and joined them using Lowess smoothing lines.   
Sex-specific trends of HF hospitalization rates were explored using negative binomial 
regression models and results are expressed as incidence rate ratios (IRRs) with corresponding 
95% confidence intervals (CIs). They estimate the average annual change in rates over the study 
period. 
In patients surviving the incident HF hospitalization, we assessed age-adjusted changes in short 
(30 days) and long (three years) term risk of a first HF recurrence or CVD-related readmission, 
using Fine and Grey competing risk regression, with death as a competing risk event. To ensure a 
minimal equal follow up time for all study participants, we included in 30-day analyses incident 
HF hospitalizations between January 1, 2000 and December 1, 2014. Consequently, incident HF 
hospitalizations occurring between January 1, 2000 and December 31, 2011 were included in 
three-year analyses.  
The proportional hazards assumption for the competing risk models were evaluated by tests of 
time-varying effects and inspection of Schoenfeld residuals and were not found to be violated. 
Lastly, we present changes over time in the proportion of patients experiencing one or multiple HF 
recurrences and analyzed changes over time in the odds of in-hospital mortality during an incident 
or recurrent HF hospitalization. 
Analyses were conducted separately for men and women, using Stata (Stata Corp LP, 4905 
















Over the study period, 142 109 hospitalizations (54.7% among men; 38.8% due to incident HF 
episodes) with HF as primary diagnosis were registered in Norway.  
Mean (SD) age at hospitalization was 77.8 (11.7) years. Men were on average younger than 
women (P<0.001) (Table 1). After adjusting for age, atrial fibrillation (AF), valvular heart disease, 
hypertension, anemia and thyroid diseases were more prevalent among women while coronary 
heart disease (CHD), cerebrovascular disease, diabetes mellitus (DM), chronic obstructive 
pulmonary disease (COPD), renal failure and neoplasms were more prevalent among men (Table 
1).  
In men, the prevalence of AF, DM, hypertension, and renal failure increased while the 
prevalence of IHD, cerebrovascular disease, valvular heart disease, COPD and neoplasms 
decreased over time. The number of medical conditions also increased over time (Supplementary 
material online, Table 1). 
In women, age at hospitalization increased over time, as did the prevalence of AF, 
hypertension, COPD, renal failure and anemia while the prevalence of CHD, cerebrovascular 
disease and DM decreased. Similar to men, we observed an increase over time in the number of 
medical conditions (Supplementary material online, Table 2). 
Over the study period, we observed a slight increase in age at hospitalization, driven by increasing 
age at hospitalizations for recurrent events in men and all hospitalizations in women. 
(Supplementary material online, Table 3).  
Trends in heart failure hospitalization rates 
Incident hospitalizations 
From 2000 to 2014, the number of hospitalizations decreased in men by 12.2% (from 2055 to 
1805) and in women by 17.2% (from 1962 to 1625) (Supplementary material online, Table 3). 
Age-adjusted hospitalization rates decreased 1.9% per year (IRR=0.981, 95% CI: 0.976-0.987) in 
men and 1.8% per year (IRR=0.982, 95% CI: 0.972-0.991) in women (P interaction = 0.52) (Figure 1, 
Table 2).  
Hospitalization rates remained unchanged in patients < 50 years and declined 2.5%, 3.2% and 
1.0% per year in men and 0.9%, 2.7% and 1.3% per year in women among patients 50-69 years, 
70-79 years and 80+ years, respectively (all P trend <0.001) (Figure 1, Table 2).  
Total hospitalizations 
From 2000 to 2014, the number of hospitalizations increased in men by 22.7% (from 4583 to 
5623) and decreased in women by 4.7% (from 4229 to 4031) (Supplementary material online, 
Table 3). Age-adjusted hospitalization rates did not change significantly in either men or women 
(Figure 2, Table 2). In men, hospitalization rates increased 2.2% per year in age group 15-49 years 
and did not change across other age groups. In women, hospitalization rates declined 1.1% and 
1.8% in age groups 50-69 years and 70-79 years, respectively (Figure 2, Table 2). 
Readmissions following an incident heart failure hospitalization 
Risk of heart failure recurrences 
Table 3 summarizes the burden and time trends in the risk of the first HF recurrence at 30 days and 
three years of follow up. Overall, 6.1% of men and 5.6% of women surviving the incident HF 
hospitalization had a HF recurrence. The age-adjusted risk of recurrences at 30 days increased 
1.7% per year (P trend<0.001) in men but did not change in women.  
Overall, 28.0% of men and 25.7% of women surviving the incident HF hospitalization had a HF 
recurrence at three years of follow up. The age-adjusted risk of recurrences increased 1.2% per 
year (P trend<0.001) in men and did not change in women (Table 3).  
The proportion of patients experiencing a recurrence at 30 days and three years was similar across 
age groups. 
Age group-specific analyses revealed no statistically significant changes in the risk of 
recurrences, except for elderly (80+ years) men (for 30-day and three-year analyses) and women 
(only for three-year analyses) (Table 3).  
Readmissions with a cardiovascular condition 
The overall, sex and age group-specific proportions of patients with a CVD-related readmission at 
30 days and three years of follow up are summarized in Table 4. The observed proportion of HF 
patients with a CVD-related readmission at 30 days was 11.7% in men and 10.2% in women. The 
age-adjusted risk of CVD-related readmissions at 30 days increased in men 1.5% per year (P 
trend<0.001) but did not change significantly in women. The observed proportion of HF patients 
with a CVD-related readmission at three years was 55.6% in men and 49.7% in women. The risk 
of CVD-related readmissions at three years increased in men 1.0% per year (P trend<0.001) but did 
not change significantly in women.  
Age group-specific analyses revealed no statistically significant changes in the risk of CVD-
related readmissions, except for men age 70-79 years (for three-year analyses) and 80+ years (for 
30-day and three-year analyses) as well as women age 80+ years (only for three-year analyses) 
(Table 4).  
In-hospital mortality 
We analyzed changes over time in the odds of surviving each HF hospitalization and summarized 
the results in Table 4, Supplementary material online. The odds of surviving the incident HF 
hospitalization increased 4.7% per year in men and 3.6% per year in women (both P trend<0.001). 
Similarly, the odds of surviving a second or later HF hospitalization increased 5.8% and 2.1% in 




















In Norway, incident HF hospitalization rates declined in both men and women at a comparable 
pace from 2000 through 2014. Total HF hospitalization rates on the other hand did not decline in 
either men or women. We observed an increased risk of HF recurrences (confined to men) in the 
context of a reduced in-hospital mortality for each HF episode. The CVD-related readmissions 
following an incident HF hospitalization were frequent, and their risk increased over time only 
among men. 
Declines in incident HF rates were reported from Olmsted County, Minnesota (2000-2010),6 
Ontario, Canada (1997-2007)19 and more recently from England (2002-2014)20 while in New 
Zealand (1988-2008)8 and Denmark (1983-2012),9 incident HF rates were characterized by a 
biphasic pattern (i.e. initial increase followed by decline). Total HF events rates declined in the US 
(2006-2014),13 Western Australia (1990-2005),11 Sweden (2002-2007)21 and France (2000-2012)12 
but increased from 2003 up to 2007 and then flattened through 2013 in Spain.14  
Of studies addressing both types of events, a decline in HF incidence and increased prevalence 
of HF was observed earlier in the US (1994-2003)22 while in Western Australia, both incident and 
total HF hospitalization rates declined (1990-2005). 11  
The 30-day HF readmission rates did not change among Medicare beneficiaries in the US (2004-
2006)23 while one-year HF readmission rates increased in Scotland (1986-2003)7 and declined in 
Ontario, Canada (1997-2007).19  
Of patients discharged from an index HF hospitalization in the US and Canada (2005-2015), the 
30-day CVD readmission rates were comparable to ours and declined modestly over time.24 In 
Spain (2003-2013)25 however, 30-day CVD-related readmission rates increased over time.  
 
Factors associated with the observed trends 
HF represents the impairment of cardiac function secondary to various cardiac and non-cardiac 
diseases and reflects the severity of the underlying condition and quality of care for the underlying 
event. CHD is the main underlying cause of HF.26 In Norway, incident acute myocardial infarction 
(AMI) incident17 and recurrence27 rates have declined at a comparable magnitude in both men and 
women while invasive treatment during the early phase of the disease has improved significantly.28 
These changes led to a reduction in the proportion of HF incidence cases attributable to CHD. 
Further, the observed reduction in HF incidence rates is attributed to reductions in systolic and 
diastolic blood pressure and prevalence of hyperlipidemia.29 30 A recent publication reported a 
decline in the incidence of type 2 DM in Norway.31 On the other hand, increases in the prevalence 
of atrial fibrillation, valvular heart disease,32 overweight30 and obesity33 have a negative impact on 
incident HF hospitalization rates.   
Readmission rates are influenced by burden of medical conditions, quality of treatment (of both 
HF symptoms and the underlying condition) as well as secondary prevention measures. In our 
study, the prevalence of conditions that can cause HF was high, ranging from 42.6% for atrial 
fibrillation to 18.6% for valvular heart disease and DM. Further, 51.9% of HF patients had two or 
more (up to seven) other medical conditions. The prevalence of these conditions increased over 
time (except for CHD), as did the number of medical conditions. Clustering of many medical 
conditions renders the management of the incident HF episode challenging, leading to suboptimal 
results and eventually increased risk for other HF recurrences.  
The observed increase in the risk of readmissions should be interpreted in the context of a 
continuous improvement in survival following hospitalization for a HF episode. We observed a 
significant increase in the odds of surviving hospitalization for both first and recurrent HF 
episode(s), likely reflecting increased use of evidence-based treatment. These findings are in line 
with a previous publication showing increases in number of days alive following an incident HF 
hospitalization.8 Taking together, these findings underline the importance of preventing HF 
recurrences in order to reduce the economic burden of HF in the community. Combined efforts to 
target metabolic risk factors, optimize timely treatment of the underlying condition and strengthen 
secondary prevention measures would help reducing mortality associated due to cardiometabolic 
diseases while keeping the risk of heart failure low. 
Strength and limitations 
The national coverage, ability to distinguish between incident and recurrent events, evaluation of 
both short and long-term outcomes as well as complete follow up of the study participants 
strengthen our study.   
When interpreting our results one need to take into account some limitations inherent to study 
design and data content. Administrative databases do not contain information on clinical indicators 
of severity such as ejection fraction (EF) or type of HF (systolic versus diastolic). However, data 
from the US indicate that changes in the rates of HF with preserved and reduced EF have followed 
similar patterns.6 Further, we did not have information on some relevant lifestyle factors such as 
smoking, lipid profile and diabetes. Nor did we have information on treatment while at hospital 
and/or following HF discharge. 
Trends of incident HF hospitalization rates may not capture the true incidence of HF in the 
community. In the last decades, there has been a shift in HF diagnostic setting from hospitals 
toward outpatient clinics.34, 35 A study conducted in Ontario19 demonstrated a decline in rates of 
both hospitalized and not hospitalized new HF cases, but whether these findings are generalizable 
to other locations is not known. Nevertheless, HF hospitalization is a god measure of severe HF 
episodes and capture the hospital-associated economic burden of the disease.  
Although the quality of coding CVD conditions in administrative data in Norway is good,36, 37 
no previous study has specifically focused on HF in Norway. Based on studies from other Nordic 
countries, the positive predictive value and specificity of HF is high but its sensitivity is lower.38, 39  
 on the premise that no previous 
hospitalization with the same discharge diagnosis was identified up to 6 years prior to the index 
event. Although this method carries the risk of misclassifying a proportion of prevalent cases as 
incident, it avoids changes over time in the accuracy of identifying true incident event. 
Conclusion: Over a 15-year period, incident HF hospitalization rates declined at a comparable 
pace in both men and women in Norway. However, increased risk of experiencing recurrences in 
the context of reduced in-hospital mortality following an HF episode swept away the positive 
effect of trends in incident HF hospitalizations, leading to no improvements in total HF 
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Age-standardized rates of hospitalizations with an incident heart failure episode in men (upper 
panel) and women (lower panel) in Norway, 2000-2014: overall and by admission type. 
 
Figure 2  
Age-standardized rates of hospitalizations with any (incident or recurrent) heart failure episode in 
men (upper panel) and women (lower panel) in Norway, 2000-2014: overall and by admission 
type.









Age, mean (SD) 77.8 (11.7)  74.9 (11.9)  81.2 (10.5)  <0.001 
Type of event, n (%)       <0.001 
Incident (first) 55 119 (38.8)  28 222 (36.3)  26 897 (41.8)   
Recurrent 86 990 (61.2)  49 484 (63.7)  37 506 (58.2)   
Admission type b       0.002 
Acute 41 830 (85.2)  22 857 (81.4)  18 973 (90.4)   
Non-acute 7238 (14.8)  5226 (18.6)  2012 (9.6)   
Medical conditions, n (%)        
Atrial fibrillation 60 481 (42.6)  32696 (42.1)  27785 (43.1)  <0.001 
Coronary heart disease 57 637 (40.6)  35532 (45.7)  22105 (34.3)  <0.001 
Hypertension 30 860 (21.7)  14 791 (19.0)  16 069 (25.0)  <0.001 
Valvular heart disease 26 385 (18.6)  12108 (15.6)  14277 (22.2)  <0.001 
Diabetes mellitus 26 588 (18.6)  15332 (19.7)  11256 (17.5)  0.057 
Renal failure 23 344 (16.4)  14764 (19.0)  8580 (13.3)  <0.001 
Chronic obstructive pulmonary disease 18 298 (12.9)  10633 (13.7)  7665 (11.9)  <0.001 
Anemia 7565 (5.3)  3706 (4.8)  3859 (6.0)  <0.001 
Neoplasms 7565 (4.8)  4403 (5.7)  2354 (3.9)  <0.001 
Cerebrovascular disease 5690 (4.0)  3205 (4.1)  2485 (3.9)  0.001 
Number of medical conditions, n (%)       <0.001 
0 19 810 (13.9)  10 168 (13.0)  9642 (15.0)   
1 48 549 (34.2)  25 794 (33.2)  22 755 (35.3)  <0.001 
2 43 430 (30.6)  24 057 (31.0)  19 373 (30.1)  <0.001 
 30 320 (21.3)  17 687 (22.8)  12 633 (19.6)  <0.001 
a Adjusted for age. 
b Information valid only during 2010-2014. 
 
 
Table 2. Age-adjusted average annual changes of incident and total (incident and recurrent) heart failure hospitalization rates in Norway, 2000-
2014 
Age group Incident hospitalizations Total hospitalizations 
  Men Women Men Women 
  No. IRR (95% CI) No. IRR (95% CI) No. IRR (95% CI) No. IRR (95% CI) 
          
All ages 28 222 0.981 (0.976-0.987) 26 897 0.982 (0.972-0.991) 77 706 1.004 (0.993-1.016) 64 403 0.995 (0.982-1.008) 
 15-49y 1214 0.995 (0.981-1.009) 510 0.984 (0.960-1.008) 2583 1.022 (1.008-1.037) 1057 1.018 (0.996-1.041) 
 50-69y 7169 0.975 (0.969-0.982) 2923 0.981 (0.973-0.989) 19 606 0.997 (0.991-1.003) 6383 0.989 (0.981-0.997) 
 70-79y 7948 0.968 (0.962-0.974) 5627 0.973 (0.965-0.982) 23 384 0.996 (0.991-1.002) 13 726 0.982 (0.976-0.988) 
 80+y 11 891 0.990 (0.982-0.999) 17 837 0.987 (0.977-0.997) 32 133 1.007 (0.998-1.016) 43 237 1.001 (0.987-1.013) 





















Table 3. Age-adjusted annual average changes in 30-day and three-year risk of recurrences following discharge from the incident heart failure 
hospitalization in Norway, 2000-2014  
 
Age group Men   Women 
  HF recurrence / 
Population at risk (%) 




HF recurrence /  
Population at risk (%) 






      
All ages 1589 / 25 902 (6.1) 26.8 (8.5) 1.017 (1.007-1.030) 1363 / 24 566 (5.6) 26.4 (8.9) 1.011 (0.998-1.023) 
15-49y 72 / 1131 (6.4) 27.9 (6.9) 1.056 (0.997-1.119) 35 / 486 (7.0) 27.6 (7.4) 1.032 (0.954-1.117) 
50-69y 477 / 6755 (7.1) 28.0 (6.7) 1.019 (0.997-1.041) 154 / 2748 (5.6) 28.0 (6.8) 1.011 (0.974-1.048) 
70-79y 435 / 7360 (5.9) 27.3 (7.8) 1.003 (0.982-1.024) 286 / 5209 (5.5) 27.2 (7.9) 1.006 (0.979-1.033) 
80+y 605 / 10 656 (5.7) 25.6 (9.7) 1.025 (1.006-1.044) 888 / 16 123 (5.5) 25.9 (9.5) 1.011 (0.995-1.027) 
Within  
three years 
      
All ages 5833 / 20 792 (28.1) 627.2 (461.1) 1.012 (1.005-1.020) 5136 / 19 942 (25.8) 603.3 (460.5) 1.007 (0.999-1.015) 
15-49y 219 / 908 (24.1) 814.4 (438.8) 1.004 (0.965-1.043) 81 / 394 (20.6) 823.5 (442.4) 1.026 (0.957-1.099) 
50-69y 1511 / 5372 (28.1) 761.3 (448.2) 1.009 (0.993-1.023) 514 / 2158 (23.8) 771.2 (446.2) 1.012 (0.986-1.038) 
70-79y 1792 / 6083 (29.5) 664.5 (452.4) 1.008 (0.994-1.021) 1160 / 4306 (26.9) 694.7 (445.9) 1.000 (0.983-1.017) 
80+y 2311 / 8429 (27.4) 502.6 (443.3) 1.024 (1.011-1.036) 3381 / 13 084 (25.8) 541.1 (451.2) 1.012 (1.002-1.022) 












Table 4. Age-adjusted annual changes in 30-day and three-year risk of cardiovascular-related readmissions following discharge from the incident 
heart failure hospitalization in Norway, 2000-2014  
 
Age group Men   Women 
 CVD readmission /  
Population at risk (%) 




CVD readmission /  
Population at risk (%) 






      
All ages 3025 / 25 902 (11.7) 26.0 (9.1) 1.015 (1.007-1.023) 2491 / 24 566 (10.2) 25.8 (9.4) 1.006 (0.996-1.015) 
15-49y 173 / 1131 (15.3) 26.6 (8.3) 1.017 (0.982-1.053) 68 / 486 (14.0) 26.6 (8.4) 1.001 (0.946-1.057) 
50-69y 944 / 6755 (14.0) 27.0 (7.6) 1.005 (0.991-1.020) 331 / 2748 (12.0) 27.1 (7.8) 0.989 (0.965-1.014) 
70-79y 852 / 7360 (11.6) 26.5 (8.5) 1.014 (0.999-1.030) 556 / 5209 (10.7) 26.6 (8.6) 1.005 (0.986-1.024) 
80+y 1056 / 10 656 (9.9) 25.1 (10.1) 1.024 (1.010-1.039) 1536 / 16 123 (9.5) 25.3 (9.9) 1.009 (0.997-1.021) 
Within  
three years 
      
All ages 11 589 / 20 792 (55.7) 457.3 (441.1) 1.010 (1.005-1.016) 9924 / 19 942 (49.8) 478.2 (444.1) 1.005 (0.999-1.011) 
15-49y 514 / 908 (56.6) 528.2 (484.4) 1.012 (0.986-1.037) 191 / 394 (48.5) 582.0 (494.7) 1.008 (0.967-1.053) 
50-69y 3276 / 5372 (61.0) 497.4 (465.8) 1.003 (0.993-1.013) 1180 / 2158 (54.7) 541.3 (473.4) 0.997 (0.981-1.014) 
70-79y 3538 / 6083 (58.2) 484.0 (443.4) 1.014 (1.005-1.024) 2306 / 4306 (53.6) 530.5 (454.7) 1.005 (0.993-1.016) 
80+y 4261 / 8429 (50.6) 407.8 (415.3) 1.017 (1.008-1.026) 6247 / 13 084 (47.8) 449.0 (431.9) 1.009 (1.002-1.017) 
 
CVD: cardiovascular disease, SD: standard deviation, SHR: sub-hazard ratio, CI: confidence interval.  
 



